Device Center Change May Cast Shadow On Woodcock's Future At CDER
This article was originally published in The Tan Sheet
Executive Summary
The pharmaceutical industry should weigh the resignation of Center for Devices and Radiological Health Director Dan Schultz in the context of what it means for their interactions with FDA's drug and biologics centers
You may also be interested in...
FDA Enforcement Follow-Through Could Thin Out Violators
FDA's emphasis on follow-through in its revamped enforcement strategy may help weed out bad actors from legitimate industry
Generic Lovenox In EU Will Require Clinical Data, Shrinking Sandoz’s Opportunity
An EU guidance issued earlier this year requiring clinical trials for generic copies of low molecular weight heparins may just have shot the European market opportunity for Momenta and its partner Sandoz, according to Momenta's CFO Rick Shea
FDA Scientists Say Plan B Decision-Makers At CDER “Should Be Removed”
A group of FDA scientists is calling for the removal of agency leaders who are suspected of politically motivated decisions regarding the emergency contraceptive Plan B